https://www.thebodypro.com/article/is-virologic-failure-best-endpoint-clinical-trials-integrase-inhibitors
HIV Treatment StrategiesInterviews

Is Virologic Failure the Best Endpoint in Clinical Trials for Integrase Inhibitors?

Toby Pepperrell
Toby PepperrellCourtesy of subject

    “Time to rethink endpoints for new clinical trials of antiretrovirals? Long-term re-suppression of HIV RNA with integrase inhibitors,” AIDS. November 12, 2019. ncbi.nlm.nih.gov/pubmed/31725428

    Terri Wilder, M.S.W.

    Terri Wilder, M.S.W.

    Terri L. Wilder, M.S.W., has been part of the HIV community since 1989, and has been a reporter and writer for TheBody/TheBodyPro since 2007.